article thumbnail

Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association

Circulation

In addition, exposure of the fetus or neonate to either persistent arrhythmias or antiarrhythmic medications may have yet-to-be-determined long-term developmental consequences. Treatment options are limited in the fetus and neonate because of limited vascular access, patient size, and the significant risk/benefit ratio of any intervention.

article thumbnail

Tachyarrhythmias in congenital heart disease

Frontiers in Cardiovascular Medicine

Surgical modifications and hemodynamic changes increase the susceptibility to arrhythmias, impacting morbidity and mortality rates, with arrhythmias being the leading cause of hospitalizations and sudden deaths. Macroreentrant atrial tachycardias, particularly cavotricuspid isthmus-dependent flutter, are frequently reported.

article thumbnail

Microvascular disease and arrhythmias: a renewed focus on the myocardial microvasculature?

Heart BMJ

Arrhythmias, and in particular atrial fibrillation (AF), are one of the greatest healthcare challenges of our time. Arrhythmia prediction models have long relied on conventional risk factors such as age, diabetes, hypertension, and history of myocardial infarction and heart failure.

article thumbnail

The real-world incidence of severe QT prolongation in patients taking antipsychotic drugs

HeartRhythm

The increased risk of arrhythmias and sudden cardiac death (SCD) caused by drug-induced QT prolongation has been a prominent safety pharmacology concern for the last 30 years.

article thumbnail

Ruxolitinib as a CaMKII Inhibitor for the Treatment of Cardiac Arrhythmias: Applications and Prospects

HeartRhythm

Recent studies have highlighted the critical role of calcium/calmodulin-dependent protein kinase II (CaMKII) overactivation in the pathogenesis of various cardiac arrhythmias.

article thumbnail

Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the Laminar Left Atrial Appendage Elimination Device?

DAIC

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi , announced the commencement of patient cases with the investigational Laminar Left Atrial Appendage Elimination (LAAX) System as part of its pivotal investigational device exemption (IDE) study. The acquisition of Laminar, Inc.

article thumbnail

Correction to: Pharmacological Management of Cardiac Arrhythmias in the Fetal and Neonatal Periods: A Scientific Statement From the American Heart Association

Circulation

Circulation, Volume 149, Issue 12 , Page e996-e996, March 19, 2024.